Document and Entity Information	3 Months Ended
Document and Entity Information	Mar. 31, 2014	May 02, 2014
Document And Entity Information
Entity Registrant Name	TherapeuticsMD, Inc.
Entity Central Index Key	0000025743
Document Type	10-Q
Document Period End Date	Mar. 31, 2014
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity a Well-known Seasoned Issuer?	No
Is Entity a Voluntary Filer?	No
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		145,439,582
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2014

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Current Assets:
Cash	$ 45,404,402	$ 54,191,260
Accounts receivable, net of allowance for doubtful accounts of $32,601 and $26,555, respectively	2,339,455	1,690,753
Inventory	920,685	1,043,618
Other current assets	2,303,522	2,477,715
Total current assets	50,968,064	59,403,346
Fixed assets, net	77,888	61,318
Other Assets:
Prepaid expense	1,630,960	1,750,455
Intangible assets	756,926	665,588
Security deposit	135,686	135,686
Total other assets	2,523,572	2,551,729
Total assets	53,569,524	62,016,393
Current Liabilities:
Accounts payable	3,068,730	2,114,217
Deferred revenue	1,478,309	1,602,580
Other current liabilities	2,271,973	3,601,189
Total current liabilities	6,819,012	7,317,986
Total liabilities	6,819,012	7,317,986
Commitments and Contingencies
Stockholders' Equity:
Preferred stock - par value $0.001; 10,000,000 shares authorized; no shares issued and outstanding
Common stock - par value $0.001; 250,000,000 shares authorized; 145,067,060 and 144,976,757 issued and outstanding, respectively	145,067	144,977
Additional paid in capital	136,321,189	135,086,056
Accumulated deficit	(89,715,744)	(80,532,626)
Total stockholders' equity	46,750,512	54,698,407
Total liabilities and stockholders' equity	$ 53,569,524	$ 62,016,393

CONDENSED CONSOLIDATED BALANCE SHEETS (Unaudited) (Parenthetical) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 32,601	$ 26,555
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	145,067,060	144,976,757
Common stock, shares outstanding	145,067,060	144,976,757

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Income Statement [Abstract]
Revenues, net	$ 2,830,533	$ 1,537,195
Cost of goods sold	830,707	380,346
Gross profit	1,999,826	1,156,849
Operating expenses:
Sales, general, and administrative	5,029,497	4,526,582
Research and development	5,908,078	1,565,201
Depreciation and amortization	13,068	7,957
Total operating expense	10,950,643	6,099,740
Operating loss	(8,950,817)	(4,942,891)
Other income and (expense)
Miscellaneous income	18,572
Interest income	9,154
Financing costs	(260,027)	(263,987)
Interest expense		(1,165,831)
Loan guaranty costs		(2,944)
Total other expense	(232,301)	(1,432,762)
Loss before taxes	(9,183,118)	(6,375,653)
Net loss	$ (9,183,118)	$ (6,375,653)
Net loss per share, basic and diluted	$ (0.06)	$ (0.06)
Weighted average number of shares outstanding	145,019,561	103,052,956

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013
Statement of Cash Flows [Abstract]
Net loss	$ (9,183,118)	$ (6,375,653)
Adjustments to reconcile net loss to net cash flows used in operating activities:
Depreciation	7,122	4,703
Amortization of intangible assets	5,946	3,254
Provision for doubtful accounts	6,046	21,795
Amortization of debt discount		1,102,680
Stock based compensation	1,009,526	542,377
Amortization of deferred financing costs	260,027	263,987
Stock based expense for services	314,291	178,959
Loan guaranty costs		2,944
Changes in operating assets and liabilities:
Accounts receivable	(654,748)	(17,978)
Inventory	122,933	277,340
Other current assets	(85,834)	(731)
Other assets	(9,154)
Accounts payable	954,513	199,445
Deferred revenue	(124,271)	(2,379)
Accrued expenses and other current liabilities	(1,329,216)	290,575
Net cash flows used in operating activities	(8,705,937)	(3,508,682)
CASH FLOWS FROM INVESTING ACTIVITIES
Patent costs, net of abandoned costs	(97,284)	(80,949)
Purchase of property and equipment	(23,692)	(22,905)
Net cash flows used in investing activities	(120,976)	(103,854)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of options	40,055
Proceeds from sale of common stock, net of costs		45,430,472
Proceeds revolving credit note		400,000
Proceeds from notes and loans payable		100,000
Repayment of revolving credit note		(400,000)
Repayment of notes payable		(4,691,847)
Net cash flows provided by financing activities	40,055	40,838,625
(Decrease) increase in cash	(8,786,858)	37,226,089
Cash, beginning of period	54,191,260	1,553,474
Cash, end of period	45,404,402	38,779,563
SUPPLEMENTAL DISCLOSURES OF CASH FLOW INFORMATION:
Cash paid for interest		191,258
SUPPLEMENTAL SCHEDULE OF NON-CASH FINANCING ACTIVITIES:
Warrants issued for financing		$ 1,711,956

THE COMPANY

3 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

THE COMPANY

NOTE 1 – THE COMPANY

TherapeuticsMD, Inc., a Nevada corporation, or TherapeuticsMD or the Company, has two wholly owned subsidiaries, vitaMedMD, LLC, a Delaware limited liability company organized on May 13, 2008, or VitaMed, and BocaGreenMD, Inc., a Nevada corporation incorporated on January 10, 2012, or BocaGreen. Unless the context otherwise requires, TherapeuticsMD, VitaMed, and BocaGreen collectively are sometimes referred to as “our company,” “we,” “our,” or “us.”

Nature of Business

We are a women’s health care product company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on conducting the clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. The current drug candidates used in our clinical trials are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis, and vaginal dryness. We are developing these hormone therapy drug candidates, which contain estradiol and progesterone alone or in combination, with the aim of demonstrating equivalent clinical efficacy at lower doses, thereby enabling an enhanced side effect profile compared with competing products. Our drug candidates are created from a platform of hormone technology that enables the administration of hormones with high bioavailability alone or in combination. In addition, we manufacture and distribute branded and generic prescription prenatal vitamins, as well as over-the-counter, or OTC, vitamins and cosmetics.

- Definition

The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 8

-URI http://asc.fasb.org/extlink&oid=28200181&loc=SL6228881-111685

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 720

-SubTopic 15

-URI http://asc.fasb.org/subtopic&trid=2122524

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6359566&loc=d3e326-107755

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6367646&loc=d3e18780-107790

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-Section 45

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=7668296&loc=d3e288-107754

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2197480

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 810

-SubTopic 10

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=18733093&loc=d3e5614-111684

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 915

-SubTopic 235

-Section 50

-Paragraph 1

-URI http://asc.fasb.org/extlink&oid=6472506&loc=d3e38932-110933

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 852

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2209116

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 272

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 275

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2134480

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 205

-SubTopic 10

-URI http://asc.fasb.org/subtopic&trid=2122150

+ Details

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

3 Months Ended

Mar. 31, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

NOTE 2 – BASIS OF PRESENTATION AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS

Interim Financial Statements

The accompanying unaudited interim condensed consolidated financial statements of TherapeuticsMD, Inc., which include our wholly owned subsidiaries, should be read in conjunction with the audited consolidated financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2013, as filed with the Securities and Exchange Commission, or the SEC, from which we derived our balance sheet as of December 31, 2013. The accompanying financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or GAAP, for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, since they are interim statements, the accompanying financial statements do not include all of the information and notes required by GAAP for complete financial statements. The accompanying financial statements reflect all adjustments, consisting of normal recurring adjustments, that are, in the opinion of our management, necessary to a fair statement of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year.

Recently Issued and Newly Adopted Accounting Pronouncements

In July 2013, the Financial Accounting Standards Board, or the FASB, issued Accounting Standards Update, or ASU, No. 2013-11, Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit when a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists (a consensus of the FASB Emerging Issues Task Force), or ASU 2013-11. The amendments in ASU 2013-11 provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in ASU No. 2013-11 do not require new recurring disclosures. The amendments in ASU 2013-11 are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments in ASU No. 2013-11 did not have a material impact on our condensed consolidated financial statements.

In December 2011, the FASB issued ASU No. 2011-11, Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities, or ASU 2011-11. ASU 2011-11 enhances current disclosures about financial instruments and derivative instruments that are either offset on the statement of financial position or subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset on the statement of financial position. Entities are required to provide both net and gross information for these assets and liabilities in order to facilitate comparability between financial statements prepared in conformity with GAAP and financial statements prepared on the basis of International Financial Reporting Standards. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those years. ASU 2011-11 did not have a material impact on our financial position or results of operations.

We do not believe there would have been a material effect on the accompanying condensed consolidated financial statements had any other recently issued, but not yet effective, accounting standards been adopted in the current period.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Impairment of Long-Lived Assets

We review the carrying values of property and equipment and long-lived intangible assets for impairment whenever events or changes in circumstances indicate that their carrying values may not be recoverable. Such events or circumstances include the following:

significant declines in an asset’s market price;

significant deterioration in an asset’s physical condition;

significant changes in the nature or extent of an asset’s use or operation;

significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;

accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;

current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and

expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

If impairment indicators are present, we determine whether an impairment loss should be recognized by testing the applicable asset or asset group’s carrying value for recoverability. This test requires long-lived assets to be grouped at the lowest level for which identifiable cash flows are largely independent of the cash flows of other assets and liabilities, the determination of which requires judgment. We estimate the undiscounted future cash flows expected to be generated from the use and eventual disposal of the assets and compare that estimate to the respective carrying values in order to determine if such carrying values are recoverable. This assessment requires the exercise of judgment in assessing the future use of and projected value to be derived from the eventual disposal of the assets to be held and used. In our assessments, we also consider changes in asset utilization, including the temporary idling of capacity and the expected timing for placing this capacity back into production. If the carrying value of the assets is not recoverable, then we record a loss for the difference between the assets’ fair value and respective carrying values. We determine the fair value of the assets using an “income approach” based upon a forecast of all the expected discounted future net cash flows associated with the subject assets. Some of the more significant estimates and assumptions include market size and growth, market share, projected selling prices, manufacturing cost, and discount rate. We base estimates upon historical experience, our commercial relationships, market conditions, and available external information about future trends. We believe our current assumptions and estimates are reasonable and appropriate. Unanticipated events and changes in market conditions, however, could affect such estimates, resulting in the need for an impairment charge in future periods. There was no impairment of intangibles or long-lived assets during the three months ended March 31, 2014 and 2013.

Fair Value of Financial Instruments

Our financial instruments consist primarily of accounts receivable, accounts payable, accrued expenses, and short-term debt. The carrying amount of accounts receivable, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such instruments, which are considered Level 1 assets under the fair value hierarchy.

We categorize our assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy as defined by Accounting Standards Codification, or ASC, 820, Fair Value Measurements. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the consolidated balance sheet at fair value are categorized based on a hierarchy of inputs, as follows:

Level 1

unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2

quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument; and

Level 3

unobservable inputs for the asset or liability.

At March 31, 2014 and December 31, 2013, we had no assets or liabilities that were valued at fair value on a recurring basis.

- Definition

The entire disclosure for all significant accounting policies of the reporting entity.

+ References+ Details

INVENTORY

3 Months Ended

Mar. 31, 2014

InventoryAbstract

INVENTORY

NOTE 4 – INVENTORY

Inventory consists of the following:

	March 31, 2014		December 31, 2013
Finished product	$	483,512	$	621,679
Raw material		257,761		250,943
Deferred costs		179,412		170,996
TOTAL INVENTORY	$	920,685	$	1,043,618

- Definition

The entire disclosure for inventory. This may include, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the major classes of inventory, and the nature of the cost elements included in inventory. If inventory is stated above cost, accrued net losses on firm purchase commitments for inventory and losses resulting from valuing inventory at the lower-of-cost-or-market may also be included. For LIFO inventory, may disclose the amount and basis for determining the excess of replacement or current cost over stated LIFO value and the effects of a LIFO quantities liquidation that impacts net income.

+ References+ Details

FIXED ASSETS

3 Months Ended

Mar. 31, 2014

Property, Plant and Equipment [Abstract]

FIXED ASSETS

NOTE 6 – FIXED ASSETS

Fixed assets consist of the following:

	March 31, 2014			December 31, 2013
Equipment	$	132,150		$	108,458
Furniture and fixtures		46,625			46,625
		178,775			155,083
Accumulated depreciation		(100,887	)		(93,765	)
TOTAL FIXED ASSETS	$	77,888		$	61,318

Depreciation expense for the three months ended March 31, 2014 and 2013 was $7,122 and $4,703 respectively.

- Definition

The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.

+ References+ Details

INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

INTANGIBLE ASSETS

NOTE 8 – INTANGIBLE ASSETS

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2014 and December 31, 2013:

	March 31, 2014
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:

OPERA® software patent	$	31,951	$	(999	)	$	30,952		15.5

Development costs of
corporate website		91,743		(91,743	)		—		n/a

Approved hormone
therapy drug
candidate patents		255,649		(3,364	)		252,285		18.75

Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents (pending)		412,406		—			412,406		n/a

Multiple trademarks for
vitamins/supplements		61,283		—			61,283		n/a
Total	$	853,032	$	(96,106	)	$	756,926

	December 31, 2013
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:

OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8

Development costs of corporate website		91,743		(89,661	)		2,082		0.3

Non-amortizing intangible assets:
Hormone therapy drug candidate patents (pending)		572,726		—			572,726		n/a

Multiple trademarks for vitamins/supplements		59,328		—			59,328		n/a
Total	$	755,748	$	(90,160	)	$	665,588

We amortize the intangible asset related to development costs for corporate website over 36 months, which is the prescribed life for software and website development costs. We amortize the intangible asset related to OPERA® using the straight-line method over the estimated remaining useful life of approximately 16 years, which is the life of the intellectual property patents. We amortize the approved hormone therapy drug candidate patents using straight-line method over the estimated remaining useful life of approximately 19 years. During the three months ended March 31, 2014 and 2013, there was no impairment recognized.

Amortization expense was $5,946 and $3,254 for the three months ended March 31, 2014 and 2013, respectively. Estimated amortization expense for the next five years is as follows:

Year Ending December 31,		Estimated Amortization
	2014 (9 months)	$	11,589
	2015	$	15,452
	2016	$	15,452
	2017	$	15,452
	2018	$	15,452

OTHER CURRENT LIABILITIES

3 Months Ended

Mar. 31, 2014

Other Liabilities, Current [Abstract]

OTHER CURRENT LIABILITIES

NOTE 9 – OTHER CURRENT LIABILITIES

Other current liabilities consist of the following:

	March 31, 2014		December 31, 2013
Accrued payroll and commission costs	$	444,749	$	941,313
Accrued vacation costs		387,908		256,920
Allowance for wholesale distributor fees		290,780		306,303
Accrued clinical research		205,000		—
Accrued offering fees		165,000		—
Accrued royalties		174,600		52,188
Accrued clinical trial costs		93,215		129,208
Allowance for coupons and returns		150,180		126,233
Accrued rent		71,257		—
Accrued legal and accounting expense		60,000		224,550
Other accrued expenses⁽¹⁾		229,284		177,900
Accrued financing costs		—		850,000
Accrued lab research		—		536,574
TOTAL OTHER CURRENT LIABILITIES	$	2,271,973	$	3,601,189

______________

⁽¹⁾In June 2008, we declared and paid a special dividend of $0.40 per share of our common stock to all stockholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2014 and December 31, 2013.

NOTES PAYABLE

3 Months Ended

Mar. 31, 2014

Notes Payable [Abstract]

NOTES PAYABLE

NOTE 10 – NOTES PAYABLE

Issuance and Payment of Multiple Advance Revolving Credit Note

On January 31, 2013, we entered into a business loan agreement with Plato and Associates, LLC, or Plato, for a Multiple Advance Revolving Credit Note, or the Revolving Credit Note. The Revolving Credit Note allowed us to draw down funding up to a $10,000,000 maximum principal amount, at a stated interest rate of 6% per annum. Plato was able to make advances to us from time to time under the Revolving Credit Note at our request, which advances were of a revolving nature and were able to be made, repaid, and made from time to time. Interest payments were due and payable on the tenth day following the end of each calendar quarter in which any interest was accrued and unpaid, commencing on April 10, 2013, and the principal balance outstanding under the Revolving Credit Note, together with all accrued interest and other amounts payable under the Revolving Credit Note, if any, was due and payable on February 24, 2014. The Revolving Credit Note was secured by substantially all of our assets. On each of February 25 and March 13, 2013, $200,000 was drawn against the Revolving Credit Note. On March 21, 2013, we repaid $401,085, which included accrued interest, and there was no balance outstanding under the Revolving Credit Note as of December 31, 2013 and February 24, 2014 when it expired. As additional consideration for the Revolving Credit Note, we granted to Plato a warrant to purchase 1,250,000 shares of our common stock at an exercise price of $3.20 per share (See Note 12).

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References+ Details

NET LOSS PER SHARE

3 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

NET LOSS PER SHARE

NOTE 11 – NET LOSS PER SHARE

We calculate basic and diluted net loss per share allocable to common stockholders using the weighted-average number of shares of common stock outstanding during the period, less any shares subject to repurchase or forfeiture. There were no shares of our common stock outstanding subject to repurchase or forfeiture for the three months ended March 31, 2014 and 2013.

Since we are in a net loss position, we have excluded outstanding stock options and restricted stock units, all of which are subject to forfeiture, as well as warrants for the purchase of our common stock from our calculation of diluted net loss per share.

The table below presents the potentially dilutive securities that would have been included in our calculation of diluted net loss per share allocable to common stockholders if they were not antidilutive for the periods presented.

	Three months ended
	March 31, 2014		March 31, 2013
Stock options		16,511,006		13,913,597
Warrants		14,293,499		13,443,499
Restricted stock units		50,000		—
		30,854,505		27,357,096

- Definition

The entire disclosure for earnings per share.

+ References+ Details

STOCKHOLDERS' EQUITY

3 Months Ended

Mar. 31, 2014

Equity [Abstract]

STOCKHOLDERS' EQUITY

NOTE 12 – STOCKHOLDERS’ EQUITY

Preferred Stock

At March 31, 2014, we had 10,000,000 shares of preferred stock, par value $0.001, authorized for issuance, of which no shares of preferred stock were issued or outstanding.

Common Stock

At March 31, 2014, we had 250,000,000 shares of common stock, $0.001 par value per share, authorized, of which 145,067,060 shares of common stock were issued and outstanding.

Issuances During the Three Months Ended March 31, 2014

During the three months ended March 31, 2014, certain individuals exercised stock options to purchase 90,303 shares of our common stock. Stock options to purchase shares of our common stock were exercised as follows: (i) 88,736 shares for $40,055 in cash and (ii) 1,567 shares, pursuant to the stock options’ cashless provision, wherein 1,433 options were cancelled.

Issuances During the Year Ended December 31, 2013

On March 14, 2013, we entered into an underwriting agreement with Jefferies LLC, or Jefferies, as the representative of the underwriters named therein, or the Jefferies Underwriters, relating to the issuance and sale of 29,411,765 shares of our common stock. The price to the public in the offering was $1.70 per share, and the Jefferies Underwriters agreed to purchase the shares of our common stock from us pursuant to the underwriting agreement at a price of $1.58 per share. The net proceeds to us from this offering was approximately $45.4 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. In addition, under the terms of the underwriting agreement, we granted the Jefferies Underwriters a 30-day option to purchase up to an additional 4,411,765 shares of our common stock. The offering closed on March 20, 2013. On April 12, 2013, the Jefferies Underwriters exercised their option to purchase an additional 1,954,587 shares of our common stock to cover over-allotments. We issued these shares to the Jefferies Underwriters on April 18, 2013 and received proceeds of approximately $3.1 million, net of expenses.

On September 25, 2013, we entered into an underwriting agreement with Stifel, Nicolaus & Company, Incorporated, as the representative of the underwriters named therein, or the Stifel Underwriters, relating to the issuance and sale of 13,750,000 shares of our common stock. The price to the public in the offering was $2.40 per share, and the Stifel Underwriters agreed to purchase the shares of our common stock from us pursuant to the underwriting agreement at a price of $2.23 per share. The net proceeds to us from this offering were approximately $30.2 million, after deducting underwriting discounts and commissions and other offering expenses payable by us. The offering closed on September 30, 2013.

During 2013 certain individuals exercised their right to purchase shares of our common stock. Stock options to purchase an aggregate of 75,423 shares of our common stock were exercised for approximately $31,000.

Warrants to Purchase Common Stock of the Company

As of March 31, 2014, we had warrants outstanding to purchase an aggregate of 14,293,499 shares of our common stock with a weighted-average contractual remaining life of 3.7 years, and exercise prices ranging from $0.24 to $3.20 per share, resulting in a weighted average exercise price of $1.79 per share.

The valuation methodology used to determine the fair value of our warrants is the Black-Scholes-Merton valuation model, or the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions, including volatility of the stock price, the risk-free interest rate and the term of the warrant.

Warrant Activity During the Three Months Ended March 31, 2014

During the three months ended March 31, 2014, we did not grant any warrants.

Warrant Activity During the Year Ended December 31, 2013

In January 2013, we granted warrants to purchase 1,250,000 shares of our common stock in connection with the issuance of the Revolving Credit Note, or the Plato Warrant, (see NOTE 10 for more details). The Plato Warrant has an exercise price of $3.20 per share. The Plato Warrant vested on October 31, 2013 and may be exercised prior to its expiration on January 31, 2019. The Plato Warrant, with a fair value of approximately $1,711,956, was valued on the date of the grant using a term of six years; a volatility of 44.29%; risk free rate of 0.88%; and a dividend yield of 0%. For the three months ended March 31, 2014 and 2013, $260,027 and $263,987, respectively was recorded as financing costs on the accompanying condensed consolidated financial statements.

In May 2013, we entered into a consulting agreement with Sancilio & Company, Inc., or SCI, to develop drug platforms to be used in our hormone replacement drug candidates. These services include support of our efforts to successfully obtain U.S. Food and Drug Administration, or the FDA, approval for our drug candidates, including a vaginal capsule for the treatment of vulvar and vaginal atrophy, or VVA. In connection with the agreement, SCI agreed to forfeit its rights to receive warrants to purchase 833,000 shares of our common stock that were to be granted pursuant to the terms of a prior consulting agreement dated May 17, 2012. As consideration under the agreement, we agreed to grant to SCI a warrant to purchase 850,000 shares of our common stock at $2.01 per share that has vested or will vest, as applicable, as follows:

283,333 shares were earned on May 11, 2013 upon acceptance of an Investigational New Drug application by the FDA for an estradiol-based drug candidate in a softgel vaginal capsule for the treatment of VVA; however, pursuant to the terms of the consulting agreement, the shares did not vest until June 30, 2013. The fair value of $405,066 for the shares vested on June 30, 2013 was determined by using the Black-Scholes Model on the date of vesting using a term of 5 years; a volatility of 45.89%; risk free rate of 1.12%; and a dividend yield of 0%. We recorded the entire $405,066 as non-cash compensation as of June 30, 2013;

283,333 shares vested on June 30, 2013. The fair value of $462,196 for these shares was determined by using the Black-Scholes Model on the date of the vesting using a term of 5 years; a volatility of 45.84%; risk free rate of 1.41%; and a dividend yield of 0%. We recorded $154,068 as prepaid expense-short term and $192,577 as prepaid expense-long term in the accompanying condensed consolidated financial statements. During the three months ended March 31, 2014, we recorded $38,517 as non-cash compensation in the accompanying condensed consolidated financial statements; and

283,334 shares will vest upon the receipt by us of any final FDA approval of a drug candidate that SCI helped us design. It is anticipated that this event will not occur before December 2015.

As of March 31, 2014, unamortized costs associated with the warrants totaled approximately $1.2 million.

Stock Options to Purchase Common Stock of the Company

On September 25, 2009, our board of directors approved the 2009 Long Term Incentive Compensation Plan, or the LTIP, to provide financial incentives to our employees, members of the board of directors, and our advisers and consultants who are able to contribute towards the creation of or who have created stockholder value by providing them stock options and other equity and cash incentives, or the Awards.

The Awards available under the LTIP consist of stock options, stock appreciation rights, restricted stock, restricted stock units, performance stock, performance units, EVA awards, and other stock or cash awards as described in the LTIP. There are 25,000,000 shares authorized for issuance under the LTIP. Under the LTIP, non-qualified stock options for the purchase of an aggregate of 14,511,006 shares of our common stock were outstanding at March 31, 2014.

On February 23, 2012, our board of directors approved the 2012 Stock Incentive Plan, and on June 10, 2013, approved the Amended and Restated 2012 Stock Incentive Plan, or the 2012 SOP. The 2012 SOP was designed to serve as an incentive for retaining qualified and competent key employees, officers and directors, and certain consultants and advisors. There are 10,000,000 shares authorized for issuance under the 2012 SOP. Non-qualified stock options for the purchase of an aggregate of 2,000,000 shares of our common stock and 50,000 restricted stock units were outstanding at March 31, 2014.

The valuation methodology used to determine the fair value of the stock options is the Black-Scholes Model. The Black-Scholes Model requires the use of a number of assumptions including volatility of the stock price, the risk-free interest rate, and the expected life of the stock options. The assumptions used in the Black-Scholes Model during the three months ended March 31, 2014 and year ended December 31, 2013 are set forth in the table below.

	Three Months Ended March 31, 2014		Three Months Ended March 31, 2013
Risk-free interest rate		1.70-1.75%		0.77-0.81%
Volatility		69.15-70.76%		43.01-44.94%
Term (in years)		5.5-6.25		5.5-6.25
Dividend yield		0.00%		0.00%

The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the expected life. Estimated volatility is a measure of the amount by which our stock price is expected to fluctuate each year during the term of an award. Our estimated volatility is an average of the historical volatility of the stock prices of our peer entities whose stock prices were publicly available. Our calculation of estimated volatility is based on historical stock prices over a period equal to the term of the awards. We used the historical volatility of our peer entities due to the lack of sufficient historical data on our stock price. The average expected life is based on the contractual term of the stock option using the simplified method.

A summary of activity under the LTIP and 2012 SOP and related information follows:

	Number of Shares Underlying Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2013		15,632,742		$	1.44		7.2	$	58,878,132
Granted		970,000		$	5.05		9.8	$	1,219,000
Exercised		(90,303	)
Expired		—
Cancelled		(1,433	)
Balance at March 31, 2014		16,511,006		$	1.66		7.4	$	76,762,626
Vested and Exercisable at March 31, 2014		11,397,538		$	0.96		6.2	$	60,999,179

The Black-Scholes Model is used to calculate the fair value of individual stock option grants on their issue date. The weighted-average issue date fair value of stock options issued during the three months ended March 31, 2014 was $3.07. On that date, we had stock options outstanding with exercise prices ranging from $0.10 to $5.21 per share. Stock-based compensation expense for stock options recognized in our results of operations for the three months ended March 31, 2014 and 2013 were $820,383 and $533,307, respectively, and stock-based expense for services for stock options recognized in our results of operations for the same periods were $185,642 and $66,653, respectively (all based on awards vested and was estimated without forfeitures). ASC 718-10 requires forfeitures to be estimated at the time of grant and revised in subsequent periods if actual forfeitures differ from the estimates. At March 31, 2014, total unrecognized estimated compensation expense related to unvested stock options previously issued was approximately $6,105,000, which is expected to be recognized over a weighted-average period of 2.5 years. No tax benefit was realized due to a continued pattern of operating losses.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 210

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.5-02.29-31)

-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 6

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 02

-Paragraph 29, 30, 31

-Article 5

Reference 4: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 310

-SubTopic 10

-Section S99

-Paragraph 2

-Subparagraph (SAB TOPIC 4.E)

-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 5: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 4

-Subparagraph (SAB TOPIC 4.C)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 6: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Article 4

Reference 7: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section C

Reference 8: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Staff Accounting Bulletin (SAB)

-Number Topic 4

-Section E

Reference 9: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 235

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.4-08.(d),(e))

-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 10: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Glossary Preferred Stock

-URI http://asc.fasb.org/extlink&oid=6521494

Reference 11: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 04

-Article 3

Reference 12: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section S99

-Paragraph 1

-Subparagraph (SX 210.3-04)

-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 14: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 3

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 15: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 11

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 16: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 5

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 17: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 10

-Section 50

-Paragraph 4

-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 18: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Regulation S-X (SX)

-Number 210

-Section 08

-Paragraph d

-Article 4

Reference 19: http://www.xbrl.org/2003/role/presentationRef

-Publisher FASB

-Name Accounting Standards Codification

-Topic 505

-SubTopic 30

-Section 50

-Paragraph 2

-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

+ Details

INCOME TAXES

3 Months Ended

Mar. 31, 2014

Income Tax Disclosure [Abstract]

INCOME TAXES

NOTE 13 – INCOME TAXES

Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or state income tax for 2014 as a result of (i) the losses recorded during the three months ended March 31, 2014, (ii) additional losses expected for the remainder of 2014, and/or (iii) net operating loss carry forwards from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As of March 31, 2014, we maintain a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References+ Details

RELATED PARTIES

3 Months Ended

Mar. 31, 2014

RELATED PARTIES

NOTE 14 – RELATED PARTIES

On February 29, 2012, Cooper C. Collins, who was then the largest shareholder of Pernix Therapeutics, LLC, or Pernix, was elected to serve on our board of directors. On October 5, 2011, we closed a stock purchase agreement with Pernix. From time to time, we have entered into agreements with Pernix in the normal course of business. All such agreements are reviewed by independent directors or a committee consisting of independent directors. During the three months ended March 31, 2014 and 2013, we did not engage in any transactions with Pernix. At March 31, 2014 and December 31, 2013, there were amounts due Pernix of approximately $46,000.

Additionally, there were amounts due to us from Pernix for legal fee reimbursement relating to a litigation matter stemming from a license and supply agreement in the amounts of $249,981 at both March 31, 2014 and December 31, 2013.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References+ Details

BUSINESS CONCENTRATIONS

3 Months Ended

Mar. 31, 2014

Risks and Uncertainties [Abstract]

BUSINESS CONCENTRATIONS

NOTE 15 - BUSINESS CONCENTRATIONS

We purchase our products from several suppliers with approximately 84% and 100% of our purchases supplied from one vendor for the three months ended March 31, 2014 and 2013, respectively.

We sell our prescription dietary supplement products to wholesale distributors, specialty pharmacies, specialty distributors, and chain drug stores that generally sell products to retail pharmacies, hospitals, and other institutional customers. Revenue generated from four major customers accounted for 97.42% and 99.46% of our recognized revenue for the three months ended March 31, 2014 and 2013, respectively.

For the three months ended March 31, 2014 and 2013, 81.75% and 70.44% of our recognized revenue and 96.08% and 99.46% of our deferred revenue was generated from sales to four major customers.

- Definition

The entire disclosure for any concentrations existing at the date of the financial statements that make an entity vulnerable to a reasonably possible, near-term, severe impact. This disclosure informs financial statement users about the general nature of the risk associated with the concentration, and may indicate the percentage of concentration risk as of the balance sheet date.

+ References+ Details

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2014

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 16 – COMMITMENTS AND CONTINGENCIES

We lease administrative office space in Boca Raton, Florida pursuant to a 63 month non-cancelable operating lease that commenced on July 1, 2013 and expires on September 30, 2018. The lease stipulates, among other things, average base monthly rents of $30,149 (inclusive of estimated operating expenses) and sales tax, for a total future minimum payments over the life of the lease of $1,899,414.

The straight line rental expense related to our current lease totaled $90,448 for the three months ended March 31, 2014 offset by rent income of $17,980. The rental expense related to our prior lease, which expired June 30, 2013 totaled $31,211 for the three months ended March 31, 2013.

As of March 31, 2014, future minimum rental payments are as follows:

Years Ending December 31,
	2014 (9 months)	$	249,458
	2015		371,240
	2016		382,377
	2017		393,848
	2018		302,859
	Total minimum lease payments	$	1,699,782

- Definition

The entire disclosure for commitments and contingencies.

+ References+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2014

Accounting Policies [Abstract]

Impairment of Long-Lived Assets

significant declines in an asset’s market price;

significant deterioration in an asset’s physical condition;

significant changes in the nature or extent of an asset’s use or operation;

significant adverse changes in the business climate that could impact an asset’s value, including adverse actions or assessments by regulators;

accumulation of costs significantly in excess of original expectations related to the acquisition or construction of an asset;

current-period operating or cash flow losses combined with a history of such losses or a forecast that demonstrates continuing losses associated with an asset’s use; and

expectations that it is more likely than not that an asset will be sold or otherwise disposed of significantly before the end of its previously estimated useful life.

Fair Value of Financial Instruments

Level 1

unadjusted quoted prices in active markets for identical assets or liabilities;

Level 2

Level 3

unobservable inputs for the asset or liability.

At March 31, 2014 and December 31, 2013, we had no assets or liabilities that were valued at fair value on a recurring basis.

FIXED ASSETS (Tables)

3 Months Ended

Mar. 31, 2014

Property, Plant and Equipment [Abstract]

Schedule of fixed assets

Fixed assets consist of the following:

	March 31, 2014			December 31, 2013
Equipment	$	132,150		$	108,458
Furniture and fixtures		46,625			46,625
		178,775			155,083
Accumulated depreciation		(100,887	)		(93,765	)
TOTAL FIXED ASSETS	$	77,888		$	61,318

Depreciation expense for the three months ended March 31, 2014 and 2013 was $7,122 and $4,703 respectively.

INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2014

Goodwill and Intangible Assets Disclosure [Abstract]

Schedule of intangible assets

The following table sets forth the gross carrying amount and accumulated amortization of our intangible assets as of March 31, 2014 and December 31, 2013:

	March 31, 2014
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:

OPERA® software patent	$	31,951	$	(999	)	$	30,952		15.5

Development costs of
corporate website		91,743		(91,743	)		—		n/a

Approved hormone
therapy drug
candidate patents		255,649		(3,364	)		252,285		18.75

Non-amortizing intangible
assets:
Hormone therapy drug
candidate patents (pending)		412,406		—			412,406		n/a

Multiple trademarks for
vitamins/supplements		61,283		—			61,283		n/a
Total	$	853,032	$	(96,106	)	$	756,926

	December 31, 2013
	Gross Carrying Amount		Accumulated Amortization			Net Amount		Weighted- Average Amortization Period (yrs.)
Amortizing intangible assets:

OPERA® software patent	$	31,951	$	(499	)	$	31,452		15.8

Development costs of corporate website		91,743		(89,661	)		2,082		0.3

Non-amortizing intangible assets:
Hormone therapy drug candidate patents (pending)		572,726		—			572,726		n/a

Multiple trademarks for vitamins/supplements		59,328		—			59,328		n/a
Total	$	755,748	$	(90,160	)	$	665,588

Schedule of estimated amortization expense

Amortization expense was $5,946 and $3,254 for the three months ended March 31, 2014 and 2013, respectively. Estimated amortization expense for the next five years is as follows:

Year Ending December 31,		Estimated Amortization
	2014 (9 months)	$	11,589
	2015	$	15,452
	2016	$	15,452
	2017	$	15,452
	2018	$	15,452

OTHER CURRENT LIABILITIES (Tables)

3 Months Ended

Mar. 31, 2014

Noncontrolling Interest [Abstract]

Schedule of other current liabilities

Other current liabilities consist of the following:

	March 31, 2014		December 31, 2013
Accrued payroll and commission costs	$	444,749	$	941,313
Accrued vacation costs		387,908		256,920
Allowance for wholesale distributor fees		290,780		306,303
Accrued clinical research		205,000		—
Accrued offering fees		165,000		—
Accrued royalties		174,600		52,188
Accrued clinical trial costs		93,215		129,208
Allowance for coupons and returns		150,180		126,233
Accrued rent		71,257		—
Accrued legal and accounting expense		60,000		224,550
Other accrued expenses⁽¹⁾		229,284		177,900
Accrued financing costs		—		850,000
Accrued lab research		—		536,574
TOTAL OTHER CURRENT LIABILITIES	$	2,271,973	$	3,601,189

______________

NET LOSS PER SHARE (Tables)

3 Months Ended

Mar. 31, 2014

Earnings Per Share [Abstract]

Schedule of potentially dilutive securities

	Three months ended
	March 31, 2014		March 31, 2013
Stock options		16,511,006		13,913,597
Warrants		14,293,499		13,443,499
Restricted stock units		50,000		—
		30,854,505		27,357,096

STOCKHOLDERS' EQUITY (Tables)

3 Months Ended

Mar. 31, 2014

Equity [Abstract]

Schedule of assumptions used in the Black-Scholes Model of stock options

The assumptions used in the Black-Scholes Model during the three months ended March 31, 2014 and year ended December 31, 2013 are set forth in the table below.

	Three Months Ended March 31, 2014		Three Months Ended March 31, 2013
Risk-free interest rate		1.70-1.75%		0.77-0.81%
Volatility		69.15-70.76%		43.01-44.94%
Term (in years)		5.5-6.25		5.5-6.25
Dividend yield		0.00%		0.00%

Schedule of Option activity

A summary of activity under the LTIP and 2012 SOP and related information follows:

	Number of Shares Underlying Stock Options			Weighted Average Exercise Price		Weighted Average Remaining Contractual Life in Years		Aggregate Intrinsic Value
Balance at December 31, 2013		15,632,742		$	1.44		7.2	$	58,878,132
Granted		970,000		$	5.05		9.8	$	1,219,000
Exercised		(90,303	)
Expired		—
Cancelled		(1,433	)
Balance at March 31, 2014		16,511,006		$	1.66		7.4	$	76,762,626
Vested and Exercisable at March 31, 2014		11,397,538		$	0.96		6.2	$	60,999,179

COMMITMENTS AND CONTINGENCIES (Tables)

3 Months Ended

Mar. 31, 2014

Commitments And Contingencies Tables

Schedule of future minimum rental payments

As of March 31, 2014, future minimum rental payments are as follows:

Years Ending December 31,
	2014 (9 months)	$	249,458
	2015		371,240
	2016		382,377
	2017		393,848
	2018		302,859
	Total minimum lease payments	$	1,699,782

INVENTORY (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Inventory
Finished product	$ 483,512	$ 621,679
Raw material	257,761	250,943
Deferred costs	179,412	170,996
Inventory	$ 920,685	$ 1,043,618

OTHER CURRENT ASSETS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Other Current Assets
Prepaid vendor deposits	$ 716,465
Prepaid research and development costs	668,548	1,267,588
Prepaid consulting	530,596	530,596
Other receivables-related party (Note 14)	249,981	249,981
Other prepaid costs	137,932	169,528
Deferred financing costs		260,022
TOTAL OTHER CURRENT ASSETS	$ 2,303,522	$ 2,477,715

- Definition

The aggregate amount of receivables to be collected from related parties where one party can exercise control or significant influence over another party; including affiliates, owners or officers and their immediate families, pension trusts, and so forth, at the financial statement date. which are usually due within one year (or one business cycle).

+ References+ Details

FIXED ASSETS (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Fixed assets, gross	$ 178,775	$ 155,083
Accumulated depreciation	(100,887)	(93,765)
Fixed Assets, net	77,888	61,318
Equipment (Member)
Fixed assets, gross	132,150	108,458
Furniture and Fixtures (Member)
Fixed assets, gross	$ 46,625	$ 46,625

PREPAID EXPENSE (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Other Assets
Prepaid research and development costs	$ 695,572	$ 824,221
Prepaid manufacturing costs	899,000	899,000
Accreted prepaid costs	36,388	27,234
TOTAL PREPAID EXPENSE	$ 1,630,960	$ 1,750,455

INTANGIBLE ASSETS (Details Narrative) (USD $)	3 Months Ended
INTANGIBLE ASSETS (Details Narrative) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Amortization expense	$ 5,946	$ 3,254
OPERA software patent (Member)
Amortization period	16 years
Hormone therapy drug candidate patents (Member)
Amortization period	19 years
Development costs for corporate website (Member)
Amortization period	36 months

INTANGIBLE ASSETS (Details ) (USD $)	3 Months Ended
INTANGIBLE ASSETS (Details ) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Finite-Lived Intangible Assets
Accumulated Amortization	$ (96,106)		$ (90,160)
Indefinite-Lived Intangible Assets
Gross Carrying Amount			755,748
Net Amount			665,588
Gross Carrying Amount	853,032		755,748
Net Amount	756,926		665,588
Hormone therapy drug candidate patents (Member)
Finite-Lived Intangible Assets
Gross Carrying Amount	255,649
Indefinite-Lived Intangible Assets
Gross Carrying Amount	412,406		572,726
Net Amount	412,406		572,726
Multiple trademarks for vitamins/supplements (Member)
Indefinite-Lived Intangible Assets
Gross Carrying Amount	61,283		59,328
Net Amount	61,283		59,328
OPERA software patent (Member)
Finite-Lived Intangible Assets
Gross Carrying Amount	31,951		31,951
Accumulated Amortization	(499)		(499)
Net Amount	23,722		31,452
Weighted Average Amortization Period	15 years 6 months	15 years 9 months 15 days
Development costs for corporate website (Member)
Finite-Lived Intangible Assets
Gross Carrying Amount	91,743		91,743
Accumulated Amortization	(89,661)		(89,661)
Net Amount	$ 14,584		$ 2,082
Weighted Average Amortization Period		4 months
Hormone therapy drug candidate patents (Member)
Finite-Lived Intangible Assets
Weighted Average Amortization Period	18 years 9 months

INTANGIBLE ASSETS (Details 1) (USD $)	Dec. 31, 2013
Goodwill and Intangible Assets Disclosure [Abstract]
2014 (9 months)	$ 11,589
2015	15,452
2016	15,452
2017	15,452
2018	$ 15,452

OTHER CURRENT LIABILITIES (Details Narrative) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Other Liabilities, Current [Abstract]
Date dividend declared	2010-06	2010-06
Dividends Payable, amount per share	$ 0.40	$ 0.40
Unclaimed dividends	$ 41,359	$ 41,359

OTHER CURRENT LIABILITIES (Details) (USD $)

Mar. 31, 2014

Dec. 31, 2013

Other Liabilities, Current [Abstract]

Accrued payroll and commission costs

$ 444,749

$ 941,313

Accrued vacation

387,908

256,920

Allowance for wholesale distributor fees

290,780

306,303

Accrued clinical research

205,000

Accrued offering fees

165,000

Accrued royalties

174,600

52,188

Accrued clinical trial costs

93,215

129,208

Allowance for coupons and returns

150,180

126,233

Accrued rent

71,257

Accrued legal and accounting expense

60,000

224,550

Other accrued expenses

229,284

^[1]

177,900

^[1]

Accrued financing costs

850,000

Accrued lab research

536,574

TOTAL OTHER CURRENT LIABILITIES

$ 2,271,973

$ 3,601,189

[1]	In June 2008, we declared and paid a special dividend of $0.40 per share of our Common Stock to all shareholders of record as of June 10, 2008, of which $41,359 remained unclaimed by certain shareholders at March 31, 2014 and December 31, 2013.

NOTES PAYABLE (Details Narrative) (Multiple Advance Revolving Credit Note (Plato Warrant) (Member), USD $)	0 Months Ended
	Mar. 21, 2013	Mar. 13, 2013	Feb. 25, 2013	Jan. 31, 2013
Multiple Advance Revolving Credit Note (Plato Warrant) (Member)
Debt Instrument [Line Items]
Maximum principal amount				$ 10,000,000
Stated interest rate				6.00%
Description of interest payment				Interest payments were due and payable on the tenth day following the end of each calendar quarter
Proceeds from revolving credit note		200,000	200,000
Repayment of revolving credit note	$ 401,085
Number of shares purchased				1,250,000
Exercise price of warrants (in dollars per unit)				3.20

NET LOSS PER SHARE (Details)	3 Months Ended
NET LOSS PER SHARE (Details)	Mar. 31, 2014	Mar. 31, 2013
Anti-dilutive shares excluded from earnings per share calculation	30,854,505	27,357,096
Stock Option [Member]
Anti-dilutive shares excluded from earnings per share calculation	16,511,006	13,913,597
Warrant [Member]
Anti-dilutive shares excluded from earnings per share calculation	14,293,499	13,443,499
Restricted Stock Units [Member]
Anti-dilutive shares excluded from earnings per share calculation	50,000

- Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References+ Details

STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	3 Months Ended	0 Months Ended		3 Months Ended	0 Months Ended	3 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative) (USD $)	Mar. 31, 2014	Apr. 20, 2013 Jefferies LLC (Underwriters) (Member)	Mar. 20, 2013 Jefferies LLC (Underwriters) (Member)	Mar. 31, 2014 Jefferies LLC (Underwriters) (Member)	Sep. 25, 2013 Stifel, Nicolaus & Company - Underwriters (Member)	Mar. 31, 2014 Stock Options (Member)
Number of shares issued during the period				29,411,765	13,750,000
Share price (in dollars per share)			$ 1.70		$ 2.40
Share price to underwritters (in dollars per share)			$ 1.58		$ 2.23
Number of shares issued during the period,value				$ 45,400,000	$ 30,200,000
Additional period for purchase share				30 days
Total Additional common stock issued under shelf registration statement			4,411,765
Additional common stock issued under shelf registration statement		1,954,587
Additional common stock issued under shelf registration statement,value		3,100,000
Options to purchase shares of common stock, value	$ 31,000					$ 40,055
Options to purchase shares of common stock, shares	75,423					88,736
Numbers of options to purchase shares of common stock, cashless exercise						1,567

STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	3 Months Ended	1 Months Ended	0 Months Ended			3 Months Ended		1 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 1) (USD $)	Mar. 31, 2014	May 31, 2013 Sancilio and Company Warrants (Member)	Jun. 30, 2013 Sancilio & Company Warrants 1st Installments (Member)	May 11, 2013 Sancilio & Company Warrants 1st Installments (Member)	Jun. 30, 2013 Sancilio and Company Warrants 2nd Installments (Member)	Mar. 31, 2014 Sancilio and Company Warrants 2nd Installments (Member)	Mar. 31, 2014 Sancilio and Company Warrants 3rd Installments (Member)	Jan. 31, 2013 Multiple Advance Revolving Credit Note (Plato Warrant) (Member)	Mar. 31, 2014 Minimum (Member)	Mar. 31, 2014 Maximum (Member)
Warrants:
Warrants outstanding	$ 14,293,499
Weighted-average contractual remaining life	3 years 8 months
Weighted average exercise price	1.79
Exercise price of warrants (in dollars per share)		2.01						3.20	0.24	3.20
Unamortized costs of warrants	1,599,000
Number of shares purchased		850,000		283,333	283,333		283,334	1,250,000
Expiration date of warrants								Jan. 31, 2019
Vesting date of warrants				Jun. 30, 2013				Oct. 31, 2013
Fair value of warrants			405,066		462,196			1,711,956
Expected term			5 years		5 years			6 years
Volatility rate			1.12%		45.84%			44.29%
Risk free rate			45.89%		1.41%			0.88%
Dividend yield			0.00%		0.00%			0.00%
Number of shares purchased forfeit		833,000
Valuation method of warrants			Black-Scholes Model
Non-cash compensation recongised			405,066			38,517
Prepaid expense-short term						154,068
Prepaid expense-long term						192,577
Unamortized warrant costs	$ 1,200,000

STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	3 Months Ended
STOCKHOLDERS' EQUITY (Details Narrative 2) (USD $)	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Options purchase Common Stock of the Company:
Weighted average issue date fair value	$ 3.07
Unrecognized stock based compensation	$ 6,105,000
Restricted Stock Units (RSUs) [Member]
Options purchase Common Stock of the Company:
Number of restricted stock units outstanding	50,000
Stock Options (Member)
Options purchase Common Stock of the Company:
Stock based compensation	185,642	66,653
Exercise prices of outstanding options -lower price	$ 0.10
Exercise prices of outstanding options -upper price	$ 5.21
Weighted average period of unrecognized stock based compensation	2 years 6 months
2009 Long Term Incentive Compensation Plan (Member)
Options purchase Common Stock of the Company:
Description of plan	To provide financial incentives to employees, directors, advisers, and consultants of our company who are able to contribute towards the creation of or who have created shareholder value by providing them stock options and other stock and cash incentives, or the Awards.
Number of shares authorized for issuance	25,000,000
Number of shares issued	14,511,006
2012 Stock Incentive Plan (Member)
Options purchase Common Stock of the Company:
Description of plan	Plan was designed to serve as an incentive for retaining qualified and competent key employees, officers, directors, and certain consultants and advisors of our company.
Number of shares authorized for issuance	10,000,000
Numbers of options oustanding	2,000,000
LTIP and 2012 SOP (Member)
Options purchase Common Stock of the Company:
Numbers of options oustanding			15,632,742
Stock based compensation	$ 820,383	$ 533,307

STOCKHOLDERS' EQUITY (Details) (Stock Options (Member))	3 Months Ended
STOCKHOLDERS' EQUITY (Details) (Stock Options (Member))	Mar. 31, 2014	Mar. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum (Member)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.70%	0.77%
Expected Volatility	69.15%	43.01%
Expected term	5 years 6 months	5 years 6 months
Maximum (Member)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate	1.75%	0.81%
Expected Volatility	70.76%	44.94%
Expected term	6 years 3 months	6 years 3 months

STOCKHOLDERS' EQUITY (Details 1) (USD $)	3 Months Ended
STOCKHOLDERS' EQUITY (Details 1) (USD $)	Mar. 31, 2014
Number Options
Options Exercised	75,423
LTIP and 2012 SOP (Member)
Number Options
Options outstanding, beginning	15,632,742
Options Granted	970,000
Options Exercised	(90,303)
Options Cancelled	(1,433)
Vested and exercisable	11,397,358
Weighted Average Exercise Price
Options outstanding, beginning	$ 1.44
Granted	$ 5.05
Options outstanding, ending	$ 1.66
Vested and exercisable	$ 0.96
Weighted Average Remaining Contractual Life
Options outstanding, beginning	7 years 2 months 12 days
Granted	9 years 10 months
Options outstanding, ending	7 years 5 months
Vested and exercisable	6 years 2 months 15 days
Aggregate Intrinsic Value
Options outstanding, beginning	$ 58,878,132
Granted	$ 1,219,000
Options outstanding, ending	76,762,626
Vested and exercisable	$ 60,999,179

RELATED PARTIES (Details Narrative) (Pernix Therapeutics LLC (Member), USD $)	Mar. 31, 2014	Dec. 31, 2013
Pernix Therapeutics LLC (Member)
Related Party Transaction [Line Items]
Receivables- legal fee reimbursement	$ 249,981	$ 249,981
Payable - related party	$ 46,000	$ 46,000

- Definition

Amount for accounts payable to related parties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References+ Details

- Definition

For an unclassified balance sheet, amounts due from related parties including affiliates, employees, joint ventures, officers and stockholders, immediate families thereof, and pension funds.

+ References+ Details

BUSINESS CONCENTRATIONS (Details Narrative)	3 Months Ended
BUSINESS CONCENTRATIONS (Details Narrative)	Mar. 31, 2014	Mar. 31, 2013
Supplier Concentration Risk (Member)
Concentration Risk [Line Items]
Concentration Risk	84.00%	100.00%
Revenue - Prescription dietary (Member)
Concentration Risk [Line Items]
Concentration Risk	97.42%	99.46%
Recognized Revenue (Member)
Concentration Risk [Line Items]
Concentration Risk	81.75%	70.44%
Deferred revenue (Member)
Concentration Risk [Line Items]
Concentration Risk	96.08%	99.46%

COMMITMENTS AND CONTINGENCIES (Details Narrative) (USD $)	3 Months Ended
	Mar. 31, 2014	Mar. 31, 2013	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Non-cancelable operating lease term	63 months
Monthly Base rent of leases	$ 30,149
Future minimum lease payments	1,899,414		1,699,782
Rental Expense	90,448	31,211
Rental income	$ 17,980

COMMITMENTS AND CONTINGENCIES (Details) (USD $)	Mar. 31, 2014	Dec. 31, 2013
Future minimum rental payments
2014		$ 249,458
2015		371,240
2016		382,377
2017		393,848
2018		302,859
Total minimum lease payments	$ 1,899,414	$ 1,699,782

FIXED ASSETS (Details Narrative) (USD $)	3 Months Ended
FIXED ASSETS (Details Narrative) (USD $)	Mar. 31, 2014	Mar. 31, 2013
Property, Plant and Equipment [Abstract]
Depreciation Expense	$ 7,122	$ 4,703